CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1632039
This article is part of the Research TopicAntibody-based Novel Target Immunotherapy in Hematological MalignancyView all 3 articles
Treatment of relapsed or refractory Hodgkin's lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
Provisionally accepted
- 1Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
- 2Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The current standard treatment for relapsed or refractory Hodgkin's lymphoma involves salvage chemotherapy followed by high-dose chemotherapy and sequential autologous stem cell transplantation. However, for patients who cannot tolerate intense chemotherapy or do not meet the conditions for autologous stem cell transplantation, there is a need to explore new treatment options. We report a case of an elderly patient with multiple relapses of classical Hodgkin's lymphoma who experienced repeated disease progression despite undergoing multiple lines of treatment including novel agents such as CD30 monoclonal antibody and PD-1 monoclonal antibody. The patient finally achieved sustained remission after receiving a combination therapy of lenalidomide and PD-1 monoclonal antibody. We hope to provide hematologists with a candidate treatment option for patients with relapsed or refractory Hodgkin's lymphoma through this case report.
Keywords: Hodgkin lymphoma, Lenalidomide, PD-1 monoclonal antibodies, Relapsed / refractory, case report
Received: 20 May 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 Dong, Wang, Gao, Cheng, Ma, Zhu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guangxun Gao, Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.